Capecitabine dominant in Dukes' C colon cancer

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.563, 2008-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Capecitabine dominant in Dukes' C colon cancer

By  

Inpharma, Vol. 1, Iss. 1658, 2008-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Capecitabine versus Bolus Fluorouracil plus Leucovorin (Folinic Acid) as Adjuvant Chemotherapy for Patients with Dukes' C Colon Cancer: Economic Evaluation in an Italian NHS Setting

By Francesco Di Costanzo  

Clinical Drug Investigation, Vol. 28, Iss. 10, 2008-01 ,pp. : 645-655

Adis International

Access to resources Recommend Favorite

Capecitabine a suitable alternative in colon cancer

By  

Inpharma, Vol. 1, Iss. 1495, 2005-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Capecitabine Compared with Bolus 5-Fluorouracil/l-Leucovorin for the Adjuvant Treatment of Colon Cancer in Japan

By Shiroiwa Takeru  

PharmacoEconomics, Vol. 27, Iss. 7, 2009-07 ,pp. : 597-608

Adis International

Access to resources Recommend Favorite

Capecitabine dominant over fluorouracil/levofolinate in Japan

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 586, 2009-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite